Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

With block­buster im­munol­o­gy meds En­brel and Ote­zla al­ready in the fold, Am­gen has most­ly stood pat on in­fus­ing new blood in­to its lega­cy pipeline. But that suc­cess won’t last for­ev­er, and Am­gen is tak­ing a far-look­ing bet on a pri­vate biotech forg­ing a new path­way to treat im­mune sys­tem dis­eases.

Am­gen will pay $55 mil­lion up­front and a dev­il­ish $666 mil­lion in fu­ture mile­stones to ac­quire Seat­tle-based Rodeo Ther­a­peu­tics and its small-mol­e­cule ther­a­pies tar­get­ing the 15-prostaglandin de­hy­dro­ge­nase (15-PGDH) en­zyme po­ten­tial­ly im­pli­cat­ed in a range of in­di­ca­tions, the com­pa­nies said Tues­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN